With Humira accounting for such a significant amount of AbbVie's total sales, the entry of biosimilars will have a huge impact on the company's financials. However, AbbVie has successfully struck similar licensing deals with seven other generic manufacturers — Pfizer ( PFE - Free Report ), Momenta, Amgen ( AMGN - Free Report ), Mylan, Fresenius Kabi Sandoz and Biogen/Samsung Bioepis — to protect its U.S. revenues from the drug. Per the settlements, Humira biosimilars are expected to be launched in the United States at different times in 2023.